Noubar Afeyan has demonstrated a strong buying bias in his recent insider transactions, with a clear preference for accumulating shares in GENB (Generation Bio). According to SEC Form 4 filings, Afeyan executed two major purchases of GENB stock on March 2, 2026, each valued at $25 million, totaling $50 million in buy activity. These transactions dominate his recent trading history, as no sales were reported during the same period. Overall, his cumulative buying across all filings amounts to $50.26 million, dwarfing his total sales of just $703,305.71—a nearly 71-to-1 ratio favoring acquisitions.
Afeyan’s trading activity is concentrated in just two companies, with GENB being the primary focus. The absence of recent sales suggests a continued commitment to maintaining or increasing his position. While the filings include multiple transactions coded as "C" (indicating acquisitions or dispositions not involving direct market purchases or sales), the two $25 million purchases stand out as the most significant. The pattern reflects a sustained accumulation strategy, particularly in GENB, with no indication of divestment in the reported period. The data presents a clear directional trend: Afeyan has been a net buyer, with recent activity reinforcing that stance.
AI-assisted summary